TMC-647055

TMC-647055 is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, a key enzyme involved in the replication of the viral genome. It was developed by Janssen Pharmaceutica, a Belgium-based pharmaceutical company owned by Johnson & Johnson.

Mechanism of Action

TMC-647055 inhibits the NS5B polymerase of the hepatitis C virus, thereby preventing the replication of the viral genome. The NS5B polymerase is a RNA-dependent RNA polymerase (RdRp) that is essential for the replication of the HCV RNA genome. By inhibiting this enzyme, TMC-647055 effectively stops the virus from multiplying.

Clinical Trials

TMC-647055 has undergone Phase I and Phase II clinical trials for the treatment of chronic hepatitis C infection. In these trials, it was often used in combination with other antiviral drugs, such as simeprevir and sofosbuvir, to enhance its antiviral activity.

Side Effects

Like all drugs, TMC-647055 can cause side effects. The most common side effects reported in clinical trials include fatigue, headache, nausea, and diarrhea. However, these side effects were generally mild and did not lead to discontinuation of treatment.

Future Development

As of now, the development of TMC-647055 has been discontinued. This decision was made due to the availability of other, more effective treatments for hepatitis C. However, the drug's mechanism of action and its clinical trial results continue to contribute to our understanding of HCV and potential strategies for its treatment.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian